Abstract
Vasomotor symptoms of menopause are a major health issue faced by millions of postmenopausal women. Although menopause is considered a normal physiological transition, its deleterious effects on the overall well-being of women have long been understood by health care providers. Although hormones work best for the treatment of vasomotor symptoms, limited nonhormonal pharmacologic agents are available. A newly approved first in its class nonhormonal neuroendocrine agent called fezolinetant is available now. It is important for providers to have an in-depth understanding about the indications, benefits, and risks of this new therapeutic agent and offer it as an alternative to hormone therapy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
